Access cutting-edge sickle cell disease treatment through this clinical trial at a research site in Baltimore. Study-provided care at no cost to qualified participants.
Access sickle cell disease specialists in Baltimore at no cost
This study follows strict safety protocols and ethical guidelines
All study-related sickle cell disease treatment provided free
A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occlusive crises.
Sponsor: Novartis Pharmaceuticals
Check if you qualify for this sickle cell disease clinical trial in Baltimore, MD
If you're searching for sickle cell disease treatment options in Baltimore, MD, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Baltimore research site is actively enrolling participants for this clinical trial. You'll receive care from experienced sickle cell disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.